Kite, A Gilead Company

This early-phase trial is testing a new treatment called KITE-197 for people with large B-cell lymphoma that has come back or not responded to other treatments. KITE-197 is made from a patient's own immune cells, which are modified in a lab to better attack cancer cells. The stud…

This study tests a treatment called KTE-X19 in 25 Japanese adults whose mantle cell lymphoma or B-cell acute lymphoblastic leukemia has come back or not responded to other treatments. KTE-X19 uses a patient's own immune cells, modified to attack cancer cells. The goal is to see i…

This study tests whether a personalized cell therapy (axicabtagene ciloleucel) works better than standard treatments for people with follicular lymphoma that has come back or stopped responding. About 231 adults with this slow-growing blood cancer will receive either the cell the…

This study tests whether a one-time CAR T-cell treatment (axicabtagene ciloleucel) works better than standard chemotherapy as the first therapy for people with high-risk large B-cell lymphoma. About 300 participants will be randomly assigned to receive either the cell therapy or …

This early study tests a new gene therapy called INT2104 in 10 adults with B-cell cancers that have come back or not responded to treatment. The therapy is given as a single IV infusion and works by instructing the body to create its own cancer-fighting T cells and natural killer…

This early-phase study tests experimental cell therapies in 40 adults with relapsed and refractory multiple myeloma who have tried at least three prior treatments. The main goal is to check safety and find the right dose. While not a cure, it aims to control the disease and may l…

This study tests a new treatment called CART-ddBCMA for people with multiple myeloma that has come back or not responded to at least three prior therapies. The treatment uses a patient's own immune cells, which are modified in a lab to target and kill myeloma cells. The main goal…

This early-phase study tests KITE-363, a personalized therapy where a patient's own immune cells are modified to target and attack faulty B cells that drive autoimmune diseases like lupus and scleroderma. About 52 adults with severe, treatment-resistant forms of these conditions …

This study follows up with 1,000 people who previously received gene-modified cell therapies (like CAR T-cell therapy) in Kite-sponsored trials. The goal is to monitor long-term safety, including late side effects, growth in children, and overall survival. No new treatment is giv…